Genmab — Februar 2020
-
5 år JKY.
-
Durable response of multiple myeloma and non‐small cell lung cancer with simultaneous, biologically targeted treatment https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16393
-
Thx E L. "Whether CD38 blockade on the lung tumour cells through daratumumab may have enhanced cytotoxic T‐cell function and contributed to the excellent response of the NSCLC to pembrolizumab, as recently reported for an in‐vivo model of lung cancer, is unknown (Chen et al., 2018)." But the idea is still alive.
-
Merck ejer pembro
-
Recruitment Status : Withdrawn (Business Reasons) https://clinicaltrials.gov/ct2/show/NCT03221634
-
Nu vi snakker om BMS: "Den amerikanske medicinalkoncern Bristol-Myers Squibb, der for nyligt har gennemført det 74 mia. dollar store opkøb af biotekselskabet Celgene, har torsdag aflagt regnskab for fjerde kvartal, hvor indtjeningen overrasker positivt, mens prognoserne for 2020 er lidt til den svage side.
Aktien indikeres dog 3,0 pct. højere i det amerikanske formarked." -
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad? https://www.mdpi.com/2073-4409/9/2/378
-
-
part of Special Issue "CD38 and Disease: A Bi-Directional Cross-Talk between Pathology and Physiology" https://www.mdpi.com/journal/cells/special_issues/CD38_CD157
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind